Finger King Kong

Early 21st century, Beijing. A new drug that may rewrite the global hepatitis B treatment landscape, and a pharmaceutical acquisition involving tens of billions of capital, prompted Chen Yuan, the director of mergers and acquisitions of Sichuan Tianyi Pharmaceutical Group, to leave Chengdu and go north to join the business. He originally thought that this was just an ordinary acquisition. Until he discovered that the due diligence numbers began to contradict each other, and there were unexplained gaps hidden behind the clinical trial data. Competitors could always get ahead of the curve, and everyone who tried to get closer to the truth was paying the price in different ways. In this capital chess game that spans Beijing, Chengdu and Shanghai, pharmaceutical companies, state-owned enterprises, foreign companies, private equity funds, CROs, regulatory authorities and media reporters take turns to appear. The stories of these people unfold quietly in the cracks of the times. At the same time, Chen Yuan's life was completely changed.